Germany · Delayed Price · Currency is EUR Microbot Medical Statistics
Total Valuation
FRA:CY9D has a market cap or net worth of EUR 140.16 million. The enterprise value is 71.81 million.
| Market Cap | 140.16M |
| Enterprise Value | 71.81M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 67.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +132.48% |
| Shares Change (QoQ) | +31.81% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 13.79% |
| Float | 67.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.10 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.45 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.64 |
Financial Position
The company has a current ratio of 27.53, with a Debt / Equity ratio of 0.01.
| Current Ratio | 27.53 |
| Quick Ratio | 27.32 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.87% and return on invested capital (ROIC) is -21.13%.
| Return on Equity (ROE) | -31.87% |
| Return on Assets (ROA) | -20.17% |
| Return on Invested Capital (ROIC) | -21.13% |
| Return on Capital Employed (ROCE) | -17.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -556,978 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +151.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +151.09% |
| 50-Day Moving Average | 2.17 |
| 200-Day Moving Average | 2.18 |
| Relative Strength Index (RSI) | 55.80 |
| Average Volume (20 Days) | 265 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.96M |
| Pretax Income | -11.14M |
| Net Income | -11.14M |
| EBITDA | -11.91M |
| EBIT | -11.96M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 68.32 million in cash and 766,218 in debt, giving a net cash position of 67.55 million.
| Cash & Cash Equivalents | 68.32M |
| Total Debt | 766,218 |
| Net Cash | 67.55M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 66.67M |
| Book Value Per Share | 1.01 |
| Working Capital | 66.35M |
Cash Flow
In the last 12 months, operating cash flow was -9.36 million and capital expenditures -35,797, giving a free cash flow of -9.39 million.
| Operating Cash Flow | -9.36M |
| Capital Expenditures | -35,797 |
| Free Cash Flow | -9.39M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:CY9D does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -132.48% |
| Shareholder Yield | -132.48% |
| Earnings Yield | -7.95% |
| FCF Yield | -6.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2018. It was a reverse split with a ratio of 0.0666666667.
| Last Split Date | Sep 5, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0666666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |